The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy--Response

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-16-0566
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1)

Clinical Cancer Research
Cancer ResearchOncology
2015English

The BET Inhibitor I-Bet762 Inhibits Pancreatic Ductal Adenocarcinoma Cell Proliferation and Enhances the Therapeutic Effect of Gemcitabine

Scientific Reports
Multidisciplinary
2018English

Fluvastatin Synergistically Enhances the Antiproliferative Effect of Gemcitabine in Human Pancreatic Cancer MIAPaCa-2 Cells

British Journal of Cancer
Cancer ResearchOncology
2005English

ERK1/2 Can Feedback-Regulate Cellular MEK1/2 Levels

Cellular Signalling
Cell Biology
2015English

EZH2 Inhibition Enhances the Efficacy of an EGFR Inhibitor in Suppressing Colon Cancer Cells

Cancer Biology and Therapy
Cancer ResearchOncologyMolecular MedicinePharmacology
2014English

Macrophage-Derived Nucleosides Reduce the Efficacy of Gemcitabine

Cancer Discovery
Oncology
2019English

Antitumor Activity of Selective MEK1/2 Inhibitor AZD6244 in Combination With PI3K/mTOR Inhibitor BEZ235 in Gefitinib-Resistant NSCLC Xenograft Models

Journal of Experimental and Clinical Cancer Research
Cancer ResearchOncology
2014English

Binimetinib, a Novel MEK1/2 Inhibitor, Exerts Anti-Leukemic Effects Under Inactive Status of PI3Kinase/Akt Pathway

International Journal of Hematology
Hematology
2019English

Expression of Inhibitor of Growth 4 by HSV1716 Improves Oncolytic Potency and Enhances Efficacy

Cancer Gene Therapy
Cancer ResearchMolecular MedicineMolecular Biology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy